About Artios

Leading independent DDR company Artios has a robust pipeline of cutting-edge cancer treatments under development that have the potential to be both first- and best-in-class. A biotechnology startup called Artios Pharma is dedicated to creating cutting-edge cancer therapies. Their main field of expertise is DNA Damage Response (DDR) pathways, which are cell-based systems that recognize and fix damage to DNA. Through focusing on these pathways, Artios seeks to eradicate particular cancer types that are usually difficult to cure.
Patients with these challenging cancers are the company’s main clientele. They work in the pharmaceutical and biotechnology industries, mostly in the field of cancer therapy. DDR-targeting therapy development, research, and commercialization are the main focuses of their business strategy. They make money by working with significant pharmaceutical companies to form agreements and by selling these medications. Leading the way in DDR medication discovery are scientists Niall Martin, PhD, and Graeme Smith, PhD, who founded Artios. Their platform and pipeline for DDR-based therapeutic prospects are strong, and they include developing inhibitors with the potential to be used as monotherapies, conquering resistance to currently available DDR-targeted medicines, and extending the reach of the immune response. ART0380, an oral dosed inhibitor that targets the ataxia telangiectasia and Rad3-related protein (ATR), is one of their promising discoveries. While maintaining the integrity of DNA in healthy tissue, this inhibitor may cause damage to sensitive cancerous cells. The oral anticancer drug ART0380 is being developed as a treatment for cancer. It can be used alone or in conjunction with other drugs that damage DNA or inhibit a cancer cell’s capacity to repair damage to DNA.